| 000 | 01437 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250513142942.0 | ||
| 264 | 0 | _c19980609 | |
| 008 | 199806s 0 0 eng d | ||
| 022 | _a0028-3878 | ||
| 024 | 7 |
_a10.1212/wnl.50.5_suppl_5.s31 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJorga, K M | |
| 245 | 0 | 0 |
_aPharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers. _h[electronic resource] |
| 260 |
_bNeurology _cMay 1998 |
||
| 300 |
_aS31-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAntiparkinson Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBenzophenones _xadministration & dosage |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 | _aCatechol O-Methyltransferase Inhibitors |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aDopamine Agents _xpharmacokinetics |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLevodopa _xpharmacokinetics |
| 650 | 0 | 4 | _aNitrophenols |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 | _aTolcapone |
| 650 | 0 | 4 | _aVolunteers |
| 773 | 0 |
_tNeurology _gvol. 50 _gno. 5 Suppl 5 _gp. S31-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1212/wnl.50.5_suppl_5.s31 _zAvailable from publisher's website |
| 999 |
_c9558282 _d9558282 |
||